Nerivio relieves migraine in adolescents

January 3, 2021

Nerivio device is approved by the FDA for the acute treatment of migraine attacks in adults. A study just published in the journal Headache indicates that it may be effective in the treatment of migraine in adolescents, aged 12 to 17.

This study was open-label, which means that it was not as rigorous as the one done to get FDA approval in adults. There was no placebo arm and it was not blinded.

Forty-five participants, out of 60 who were enrolled, performed at least one treatment. There was one device-related adverse event in which a temporary feeling of pain in the arm was felt. Pain relief and pain-free status were achieved by 71% (28/39) and 35% (14/39) of participants, respectively. At 2 hours, 69% (23/33) of participants had improvement in functional ability.

Nerivio is a remote electrical neuromodulation, or REN device. It is applied to the upper arm and the current is turned up to produce a strong sensation below the pain level. It works by stimulating endogenous pain-relieving mechanisms. A recent review of various neurostimulation methods found REN to be the only one clearly proven to be effective.

Nerivio requires a prescription from a health care provider. If you don’t have one, you can consult one at a telemedicine startup, Cove (I am a consultant for Cove). It is a disposable device that costs $99 for 12 treatments. Some insurance companies pay for it.

Written by
Alexander Mauskop, MD
Continue reading
June 7, 2026
News
A new edition of my migraine book and an upcoming conversation with Dr. Sanjay Gupta
An overview of why I updated The End of Migraines: 150 Ways to Stop Your Pain for a 3rd edition, what has changed in migraine treatment, and how a more structured, realistic approach can help people who feel they’ve “tried everything.”
Read article
June 4, 2026
Research
A New Study of Meat Intake, Genetics, and Brain Health
A newly published Swedish study suggests that the relationship between diet and brain aging may be more genetically specific than previously understood. Researchers followed over 2,000 older adults for up to 15 years and found that higher meat consumption was associated with slower cognitive decline and lower dementia risk, but only in those carrying the APOE E4 genetic variant, the most common hereditary risk factor for Alzheimer's disease. This may be relevant for people with headaches.
Read article
June 3, 2026
News
Keynote address at the 22nd Annual Neuroscience Zappulla Research Day
I was honored to be delivering the keynote address at the 22nd Annual Neuroscience Zappulla Research Day on Wednesday, June 3, at the Hackensack Meridian Neuroscience Institute, JFK University Medical Center in Edison, NJ.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe